New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)

xlomafota13 shared this article with you from Inoreader New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5) Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 4:S0007-4551(21)00576-2. doi: 10.1016/j.bulcan.2021.11.012. Online ahead of print. NO ABSTRACT PMID:34996599 | DOI:10.1016/j.bulcan.2021.11.012 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.